Fig. 3: Change from baseline in pharmacodynamic biomarkers in the Q2W cohort.
From: An anti-TSLP monoclonal antibody for uncontrolled CRSwNP: the DUBHE randomized clinical trial
a Peripheral blood eosinophil count; b Tissue eosinophil count; c Hematoxylin and eosin stain of biopsied nasal polyp tissue at baseline and week 16 from a patient (magnification: ×400); d Plasma interleukin-5 (IL-5); e Plasma interleukin-13 (IL-13); f Total serum immunoglobulin E (IgE); g Serum thymus and activation-regulated chemokine (TARC); h Serum periostin; i Plasma thymic stromal lymphopoietin (TSLP). HPF high-power field; Q2W every 2 weeks. Error bars denote standard error. Baseline values are presented as mean (standard deviation). Biomarkers were analyzed under pharmacodynamic set using Wilcoxon rank-sum test. P values were two sided and nominal, without adjustments for multiplicity. No between comparison was performed during the open-label and follow-up periods as all patients received CM326 during the open-label period.
